WSL017 

WSL017 is a cytochrome bd oxidase inhibitor with antibacterial activity against Mycobacterium tuberculosis. WSL017 can be used for the research of tuberculosis^[1].

WSL017 (0.001-100 µM) competitively inhibits Mycobacterium tuberculosis cytochrome bd (Mtbd) in proteoliposomes with an IC₅₀ of 1.4 µM by binding to the quinol-binding site^[1].
WSL017 (0.001-100 µM) competitively inhibits Escherichia coli cytochrome bd (Ecbd) in proteoliposomes with an IC₅₀ of 1.7 µM by binding to the quinol-binding site^[1].
WSL017 (3 µM) does not inhibit Caldalkalibacillus thermarum type 2 NADH dehydrogenase (NDH2) activity, confirming its specific action on cytochrome bd oxidases^[1].
WSL017 (100 µM) binds to the quinol oxidation site of dimeric Escherichia coli cytochrome bd (Ecbd) via hydrophobic interactions, stabilizing the Q-loop in a closed state to inhibit enzyme activity^[1].
WSL017 (25 µM; 7 days) significantly impairs the growth of Mycobacterium tuberculosis H37ra cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

285.40

C₁₇H₁₉NOS

CCC(NC1=CC=C(SC2=CC(C)=CC=C2C)C=C1)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tijn T. van der Velden, et al. Discovery of a novel chemotype targeting Mycobacterium tuberculosis cytochrome bd through rapid screening and structural elucidation. bioRxiv. 2026.